Cartherics: An Innovative Company Developing Cellular Immunotherapy Cancer Treatments

By Karen Loudon / May 14, 2024
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Pulse 2.0 discussing Cartherics' innovative approach to using stem cells to...
Read More

The first baby from a frozen embryo turns 40!

By Karen Loudon / May 2, 2024
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Barbara Barkhausen, a German speaking, Asia-Pacific Correspondent for a variety of...
Read More

Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)

By Karen Loudon / April 26, 2024
Ian Nisbet, PhD Chief Operating Officer, Cartherics Pty Ltd As published in pharmaphorum  Background The recent acquisition of ImmunoGen by...
Read More

Cartherics enters into Collaborative Research Agreement with TiCARos

By Karen Loudon / April 2, 2024
  Melbourne, Australia, 2 April 2024 –  Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the...
Read More

Cartherics executes Option Agreement with The Ohio State University

By Karen Loudon / March 20, 2024
TISSUE FACTOR AS A NOVEL TARGET FOR CAR-NK CELLS Melbourne, Australia, 20 March 2024 –  Cartherics Pty Ltd (“Cartherics” or...
Read More

Cartherics: Leading the Charge in Immunotherapy for Solid Tumours

By Karen Loudon / March 19, 2024
At Emergence 2024, Cartherics’ COO, Dr Ian Nisbet was interviewed by Wholesale Investor. In the interview, Ian discusses the company's...
Read More

Teal Ribbon Day: Raising awareness for ovarian cancer

By Karen Loudon / February 28, 2024
Each year in Australia around 1815 women are diagnosed with ovarian cancer. In most cases the cancer will be diagnosed...
Read More

Cartherics to present and exhibit at Emergence 2024

By Karen Loudon / February 22, 2024
Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at...
Read More

Cartherics’ CEO discusses the future of solid tumour therapy

By Karen Loudon / February 15, 2024
Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the...
Read More

Ovarian cancer: Biotech company Cartherics to start human trials of new drug

By Karen Loudon / February 12, 2024
There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when...
Read More

Positive pre-IND meeting with US FDA for new ovarian cancer cell therapy

By Karen Loudon / February 1, 2024
Melbourne, Australia, 1 February 2024 –  Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the...
Read More

Cartherics to present at Australia Biologics Festival 2024

By Karen Loudon / January 23, 2024
Cartherics is pleased to announce that Dr Ian Nisbet, Chief Operating Officer, will be presenting at Australia Biologics 2024 at...
Read More

Buoyant Life Sciences Sector Emerges Stronger

By Karen Loudon / December 18, 2023
BioSpectrum Asia’s cover story in its December edition reflects on the advancement and changes that have shaped the industry in...
Read More

Chimeric Antigen Receptor (CAR) – Natural Killer (NK) Cells – Looking good for cancer therapy

By Karen Loudon / November 28, 2023
As published in Drug Target Review  Professor Alan Trounson, AO Dr Huimin Cao Dr Aleta Pupovac The suitability of NK...
Read More

Rearming the body to fight cancer

By Karen Loudon / November 15, 2023
Cartherics is currently undertaking a new capital raise to initiate clinical trials for its lead allogeneic cell therapy for ovarian...
Read More
1 2 3 12